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Abstract
Objectives Ferumoxytol is an alternative to gadolinium-based compounds as a vascular contrast agent for magnetic resonance
angiography (MRA), particularly for patients with chronic kidney disease (CKD). However, dose-related efficacy data are
lacking. We aimed to determine the optimal (minimum effective) dose of ferumoxytol for MRA in patients with CKD.
Methods Ferumoxytol-enhanced MRA (FeMRA) was performed at 3.0 T in patients with CKD after dose increments up to a
total of 4 mg/kg. Image quality was assessed by contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR) in the abdominal
aorta and inferior vena cava. Quadratic regression analyses were performed to estimate the effects of dose increments on CNR
and SNR.
Results Twenty-three patients underwent FeMRA (mean age 60 [SD 13] years, 87% men, 48% had diabetic nephropathy) with
cumulative doses of 0, 1, 2, 3 and 4 mg/kg of ferumoxytol. On regression analyses, a parabolic relationship was observed between
ferumoxytol dose and signal with progressive signal loss using doses exceeding 4 mg/kg. A dose of 3 mg/kg achieved ≥ 75% of
predicted peak CNR and SNR and images were deemed of excellent diagnostic quality.
Conclusions In patients with CKD undergoing FeMRA, a dose of 3 mg/kg provides excellent arterial and venous enhancement.
The benefits of increasing the dose to a theoretically optimal value of 4 mg/kg appear to be negligible and likely of minimal, if
any, diagnostic value.
Key Points
• Ferumoxytol is used off-label as an MRI contrast agent but dose-related data are lacking.
• In patients with CKD requiring MR angiography, a dose of 3 mg/kg provides excellent vascular enhancement.
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Abbreviations
AA Abdominal aorta
ALARA As low as reasonably achievable
CIN Contrast-induced nephropathy
CKD Chronic kidney disease
eGFR Estimated glomerular filtration rate
ERF Established renal failure
FeMRA Ferumoxytol-enhanced magnetic resonance
angiography
IDA Iron deficiency anaemia
IVC Inferior vena cava
MED Minimum effective dose
NSF Nephrogenic systemic fibrosis
PVD Peripheral vascular disease
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Introduction
Ferumoxytol, an iron oxide nanoparticle compound with
superparamagnetic properties, was originally designed as an
intravascular contrast agent for magnetic resonance imaging
(MRI) [1], although ultimately it was commercialised as an
intravenous iron therapy for anaemia. Meanwhile,
ferumoxytol is now increasingly used off-label by clinicians
and researchers as anMRI contrast agent. Vascular imaging in
patients with chronic kidney disease (CKD) can be challeng-
ing due to increased susceptibility to adverse events such as
contrast-induced nephropathy (CIN) with iodine-based con-
trast agents and concerns regarding nephrogenic systemic fi-
brosis (NSF) with gadolinium-based contrast agents
(GBCAs).
Ferumoxytol has high relaxivity at 1.5 T and 3.0 T [2] with
theoretical advantages as a contrast agent for MRA. It is not
filtered by the glomerulus but is removed from the circulation
via macrophage phagocytosis with the remaining iron oxide
particles taken up by the reticuloendothelial system of the
liver, spleen and bone marrow being incorporated into body
iron stores for red blood cell synthesis. Due to its large mo-
lecular weight of approximately 750 kD [3], ferumoxytol re-
sides in the blood pool and does not diffuse out into the ex-
tracellular fluid space. Given its long intravascular half-life, it
can potentially be used without the need for bolus timing with
imaging in a ‘steady state’ when the arterial and venous vas-
culatures are equally enhanced.
In June 2009, the US Food and Drug Administration
(FDA) approved ferumoxytol for parenteral treatment of iron
deficiency anaemia (IDA) in adults with CKD and in February
2018 expanded the approval to include all eligible adults with
IDA who cannot tolerate or have not responded to oral iron.
Recently, ferumoxytol has gained appeal in vascular imaging
and there are reports in the literature for its safe use and utility
in both adult and paediatric patients with CKD [4–11].
However, dose-related efficacy studies are lacking with differ-
ent doses having been reported in the literature, ranging from
120 mg of elemental iron as a bolus for angiographic assess-
ment of arteriovenous fistulas [4] to 6 mg/kg for T2* renal
perfusion mapping [12].
The aim of this study was to establish the optimal dose of
ferumoxytol required for vascular imaging in patients with
CKD.
Materials and methods
Study population
Patients older than 18 years of age with estimated glomerular
filtration rate (eGFR) of < 30 mL/min/1.73 m2 (including pa-
tients on haemodialysis) requiring vascular imaging were
included in this prospective, single-centre study. Patients were
referred for ferumoxytol-enhanced MR angiography
(FeMRA) if the clinician felt that an angiogram was required
for one the following indications: characterisation of the
aortoiliac vasculature prior to wait-listing for kidney trans-
plantation, investigation of renal artery stenosis or to assess
peripheral vascular disease (PVD). In all patients, standard
contrast-enhanced imaging techniques were avoided due to
potential risks of CIN or NSF. Dialysis patients were referred
for FeMRA if they had residual renal function with a risk of
decline or loss of function after use of iodine-based contrast
agents or if there was prior evidence of extensive vascular
calcifications which would impair CT images. Patients with
standard contraindications to MRI (such as non-MRI-
compatible pacemakers, severe claustrophobia and metal in
the eyes), history of allergic reaction to any intravenous iron
product, any conditions associated with iron overload and
patients with active immune or inflammatory conditions
(e.g. systemic lupus, rheumatoid arthritis) were excluded.
As ferumoxytol was increasingly used off-label in our cen-
tre as an alternative MRI contrast agent [11], this dose-finding
study was performed to optimise our protocol. This was ap-
proved by the Clinical Governance Committee of the
Diagnostics Directorate. The regional Research Ethics
Committee ethics officer was consulted and confirmed that
formal ethics committee approval was not required.
Nevertheless, as this was an off-label use of the agent, in-
formed consent was obtained from all subjects .
Investigations were performed between 1 December 2015
and 30 June 2016.
Baseline data
Age, gender and aetiology of established renal failure (ERF)
were recorded. We retrieved data on last haemoglobin and
serum creatinine prior to FeMRA and calculated the eGFR
using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [13]. All patients were
weighed on the day of the scan to calculate the doses of
ferumoxytol given.
MRI protocol
Patients underwentMRAwith ferumoxytol administered in an
appropriate setting under supervision of trained medical per-
sonnel and were observed for a minimum of 30 min following
termination of ferumoxytol infusion. All studies were per-
formed on a 3.0-T Prisma MRI scanner (Magnetom,
Siemens Healthineers) with local phased-array imaging coils
in the supine position using standardised protocol similar to
that of standard MRA studies with GBCAs.
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Ferumoxytol administration
Ferumoxytol was infused intravenously through a 22-gauge
intravenous cannula placed in the antecubital fossa of either
arm. Optimal dose was selected on the basis of the minimum
effective dose (MED) to achieve diagnostic imaging rather than
maximum signal intensity criteria similarly to the ‘As Low As
Reasonably Achievable (ALARA) principle’ employed to min-
imise radiation exposure. A total dose of 4 mg/kg of
ferumoxytol (Feraheme; AMAG Pharmaceuticals, Inc.) was
delivered up to a maximum of 400 mg. The dosage of
ferumoxytol is expressed in terms of milligram of elemental
iron, with each millilitre of ferumoxytol containing 30 mg of
elemental iron.
In all cases, ferumoxytol was diluted to a concentration no
greater than one part ferumoxytol to four parts 0.9% sodium
chloride and was administered in 4–7 (median 4) divided con-
trolled infusions (aliquots) until the maximum dose was de-
livered. Ferumoxytol infusions were delivered by an MRI-
compatible infusion pump for precise control over infusion
rates which were set at 1 ml/s of diluted ferumoxytol (equal
to 6 mg/s of elemental iron) followed by 20 ml of 0.9% sodi-
um chloride at a rate of 1 ml/s. The infusion time for each
aliquot ranged up to 18 s depending on body weight and
volume of the infusion. These aliquots were delivered with a
minimum interval of 5 min between them to allow time for
planning and different imaging components to be performed;
thus, the total dose was delivered over a minimum of 20 min.
Patients were instructed to immediately alert the operator
should they have any discomfort at any time, and were con-
tinuously monitored by pulse oximeter (measuring both heart
rate and oxygen saturation) while in the MRI scanner and had
blood pressure measured before and after infusions. Average
scan duration was 30 min.
Image acquisition
A full range of angiographic sequences were performed de-
pending on the clinical indication; however, for the purposes
of this study, the relevant one was a T1-weighted fast low-
angle shot (FLASH) sequence of aortoiliac vasculature. This
sequence was performed before giving contrast and 60 s after
each aliquot of the diluted ferumoxytol was administered
without changing the imaging field-of-view between
sequences.
Data analysis
Images were analysed using OsiriX MD (Pixmeo). For quan-
titative analysis, signal intensities within the vessel lumen
were measured using the regions of interest (ROI) placed in
the abdominal aorta (AA), inferior vena cava (IVC), psoas
muscle, intra-abdominal fat, liver and spleen that were cloned
(in terms of position and size) across the acquisitions. An ROI
was placed in air outside of the imaged body for noise calcu-
lation. The target ROI size was a minimum of 1 cm2. If this
size could not be achieved in small vessels, the largest practi-
cal ROI area for that vessel was assessed. Mean signal inten-
sity (SI; arbitrary units, U) following each dose increment was
recorded from all ROIs except those placed in air, from which
the standard deviation (SD) was recorded. Contrast-to-noise
(CNR) and signal-to-noise (SNR) ratios were calculated.
Correlation analyses between CNR and SNR in the AA and
IVC and ferumoxytol dose were performed. Assessment of
the CNR and SNR was performed independently by two ra-
diologists (MH and GR) with 5 years and > 20 years of expe-
rience, respectively, in cardiovascular MR imaging.
Following analysis of all images, discordances were adjudi-
cated by discussion and consensus reached.
Descriptive statistics are expressed as means ± SD or num-
bers and percentages. Four quadratic regression models were
used to plot the relationship between cumulative doses of
ferumoxytol and CNR and SNR change within AA and
IVC, respectively, and estimate the regression coefficients.
The open-source statistics environment R (version 3.4.3;
The R Foundation) was used for statistical analysis [14].
Results
A total of 25 patients had angiographic assessment with
FeMRA. Two patients were excluded from analysis due to
failure to acquire all repeated FLASH sequences because of
claustrophobia necessitating abandonment of the scan. From
the 23 remaining patients, 13 (57%) required imaging as part
of pre-operative kidney transplant assessment, 7 (30%) had
clinical manifestations of renovascular disease and 3 (13%)
had PVD. Five (22%) patients were on haemodialysis and 18
(78%) had various degrees of renal failure (6 of them had a
kidney transplant). The mean age was 59.8 (SD 12.8) years,
20 (87%) were men and almost half of them had diabetic
nephropathy. An average of 325 mg (SD 65) of ferumoxytol
was administered (Table 1).
The imaging parameters for the post-contrast breath-hold
MRA acquisitions are listed in Table 2. Minor changes to
these values were made on an individual basis due to differ-
ences in patient body habitus and extracellular fluid status. All
subjects completedMRAwith ferumoxytol enhancement with
no adverse events.
Cumulative doses of 0 (pre-contrast), 1, 2, 3 and 4mg/kg of
ferumoxytol yielded mean CNR of − 41 (± 36), 20 (± 26), 46
(± 29), 90 (± 66) and 86 (± 62) inAA and − 45 (± 37), 4 (± 31),
38 (± 26), 78 (± 46) and 95 (± 71) in IVC, respectively. Mean
SNR values were 35 (± 14), 92 (± 63), 97 (± 40), 155 (± 96)
and 153 (± 95) in AA and 30 (± 10), 77 (± 43), 89 (± 38), 138
(± 83) and 162 (± 109) in IVC, respectively.
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Figures 1 and 2 demonstrate the distribution of the CNR
and SNR, respectively, measured in AA and IVC against the
cumulative dose of the administered ferumoxytol. Both
graphs demonstrate a parabolic relationship between the
administered dose and vascular signal with a line of best fit
calculated by quadratic regression analysis.
The calculated relationships for the AA are described be-
low, where x represents the ferumoxytol dose and f(x) the
returned signal:
CNR : f xð Þ ¼ −6:6 xð Þ2 þ 59:4 xð Þ −34:1
with an estimated regression co-efficient (R2) = 0.56 and
SNR : f xð Þ ¼ −7:0 xð Þ2 þ 58:9 xð Þ þ 31:2
with an estimated R2 = 0.35.
These equations predict peak aortic CNR and SNR at
4 mg/kg ferumoxytol with decrease in signal with higher
doses (Tables 3 and 4). However, 85% of peak CNR in AA
is predicted to be obtained after administration of 3 mg/kg of
ferumoxytol and < 10% of SNR gain is predicted with admin-
istration of > 3mg/kg of ferumoxytol (Tables 3 and 4).
The calculated relationships for the IVC are described be-
low, where y represents the ferumoxytol dose and f(y) the
returned signal:
CNR : f yð Þ ¼ −4:4 yð Þ2 þ 50:9 yð Þ −38:1
with an estimated R2 = 0.65 and
SNR : f yð Þ ¼ −4:8 yð Þ2 þ 50:4yþ 27:2
with an estimated R2 = 0.44.
These equations predict peak IVC CNR and SNR at 6
and 5 mg/kg ferumoxytol, respectively, with decrease in
signal with higher doses. Still 75% of peak CNR in IVC
is predicted to be obtained after administration of 3 mg/kg
of ferumoxytol and < 15% of SNR gain is predicted with
administration of > 3 mg/kg of ferumoxytol (Tables 3 and
4). Examples of the images obtained are shown in Figs. 3,
4 and 5 where it is obvious that image quality was signif-
icantly improved in both arterial and venous compartments
following ferumoxytol dose increments up to 3 mg/kg but
no visual difference was apparent with higher doses.
With ferumoxytol, arteries and veins can be selectively
depicted in a single exam. However, due to the prolonged
residence of contrast in the intravascular space, there may be
overlay of the arteries and veins, and this is more pronounced
in steady-state thick maximum intensity projection (MIP) im-
ages of the peripheral vasculature (Fig. 6, Supplemental
Video 1).
Discussion
Ferumoxytol as a contrast agent results in profound shortening
of the T1 relaxation time of blood which increases the signal
in blood vessels in T1-weighted sequences. However, high
Table 1 Baseline characteristics
Age (year), mean (SD) 59.8 (12.8)
Female sex, n (%) 3 (13.0)
Body weight (kg), mean (SD) 85.4 (22.9)
BMI categories, n (%)
18.5–25 9 (39.1)
25.1–30 4 (17.4)
> 30 10 (43.5)
Cause of ERF
Diabetes, n (%) 11 (47.9)
Renovascular, n (%) 3 (13.0)
Othera, n (%) 6 (26.1)
Unknown, n (%) 3 (13.0)
Laboratory values at time of MR imaging
Haemoglobin (g/L), mean (SD) 106.4 (21.2)
Creatinine (μmoL/L), mean (SD)b 359 (131)
eGFR (mL/min/1.73m2), mean (SD)b 17.2 (7.5)
CKD stage, n (%)
HD 5 (21.7)
5 10 (43.5)
4 8 (34.8)
Dose of ferumoxytol given (mg), mean (SD) 325 (65)
a Glomerulonephritis (n = 4), reflux nephropathy (n = 1), obstructive
uropathy (n = 1)
b Excludes patients on dialysis
BMI, body mass index; ERF, established renal failure; eGFR, estimated
glomerular filtration rate; CKD, chronic kidney disease; HD,
haemodialysis
Table 2 Pulse sequence parameters for the T1-weighted FLASH
sequences
TR (repetition time) 2.88 ms
TE (echo time) 1.04 ms
Flip angle 20°
Number of averages 1
Field of view 400 × 325 mm
Section thickness 1 mm
Voxel dimensions 1.0 × 1.0 × 1.0 mm
Data matrix 243 × 384
Timing of sequencea 60 s
Acquisition time 18 s
Mean volume thickness 112
Bandwidth 300 Hz/PX
Parallel imaging acceleration factor 3
a After start of contrast infusion
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concentrations of the agent can cause artefacts [15] because of
signal loss through T2* shortening. We used incremental
doses of ferumoxytol as an MRI contrast agent for assessing
arterial and venous vasculature in patients with CKD to estab-
lish the optimal (minimum effective) dose and observed a
parabolic relationship between the administered dose and vas-
cular signal. After exceeding a threshold, a negative correla-
tion between the injected dose and the signal intensity was
confirmed which is explained by T2* shortening effects at
higher doses of ferumoxytol.
Our findings demonstrate dose-dependent improvement in
signal with ferumoxytol doses up to 3 mg/kg with no signif-
icant benefit (or even loss in signal) with higher doses of
contrast. We defined the optimal dose as the minimum effec-
tive dose to maximise diagnostic yield while minimising po-
tential for reactions. Although it could be argued that
ferumoxytol doses exceeding 3 mg/kg were predicted to
achieve better CNR and SNR in the abdominal aorta and
inferior vena cava, the gain in signal was minimal, especially
considering that a 33% increase in dose above 3 mg/kg is
Fig. 2 Distribution of SNR
measured in abdominal aorta and
IVC following incremental doses
of ferumoxytol
Fig. 1 Distribution of CNR
measured in abdominal aorta and
IVC following incremental doses
of ferumoxytol
Eur Radiol (2019) 29:3543–3552 3547
required to yield just 10% increase in signal. Our images were
judged as diagnostic when assessed by two readers. It has
been argued that peak SNR correlates poorly with the subjec-
tive quality rating because it is essentially a pixel-based fidel-
ity measurement method that does not match to the human
perception [16]. Hence, the ‘more is better’ approach is not
always applicable for SNR. We advocate that 3 mg/kg is an
acceptable dose with advantages in terms of protocol simpli-
fication, dose saving and minimisation of side effects without
compromising diagnostic accuracy.
There are no published dose-finding data on ferumoxytol
for vascular imaging with most centres using between 3 and
4 mg/kg based on limited clinical experience. Two studies
were identified to formally evaluate the ferumoxytol dose
when used as MRI contrast agent, one for MRA and the other
for lymphography and lymph node imaging. In a small pilot
study including 5 patients who had 3D MRA of the tibial
artery trifurcation at 1.5 T, escalating doses of 0.4 mg/kg of
ferumoxytol (for a total of 4 mg/kg) were administered. The
mean SNR in the arteries increased with higher doses of
ferumoxytol; however, a cut-off dose for optimal imaging
was not determined [17]. In the non-vascular study investigat-
ing ferumoxytol for MR lymphography in 15 patients under-
going prostatectomy with regional lymph node dissection, a
dose of 7.5 mg/kg was found to be safe and effective in
differentiating between malignant and benign lymph nodes
24 h after ferumoxytol injection [18].
In our initial experience, ferumoxytol has potential clinical
utility as a contrast agent for MRI. We have previously report-
ed a case series of kidney transplant candidates to examine the
feasibility of acquiring adequate aortoiliac enhancement with
FeMRA [11]. Similar MRI and ferumoxytol dosing protocols
were used and there is patient overlap between the studies.
However, the objective of this current study is fundamentally
different and the data analysis used to estimate the optimal
dose is novel. Meanwhile, we are testing ferumoxytol in pro-
spective comparative studies of FeMRA versus CT angiogra-
phy and Doppler ultrasound to assess vasculopathy in CKD
patients using similar MR angiography protocols
(ClinicalTrials.gov registration number: NCT02997046). As
ferumoxytol’s pharmacokinetics are independent of renal
function, the proposed dose of 3 mg/kg can be applied univer-
sally for MRI irrespectively of renal function. This creates the
basis for adoption of this dose in current clinical practice with
the caveat that further work is required to translate our proto-
col to 1.5 T. When given for treatment of anaemia, the li-
cenced dose of ferumoxytol is an initial 510-mg dose followed
by a second 510-mg dose 3–8 days later. This corresponds to a
dose of approximately 7.3 mg Fe/kg for a 70-kg man or a dose
of 14.6 mg Fe/kg over 3–8 days. The 3-mg/kg dose we pro-
pose for imaging is substantially lower than this therapeutic
dose (approximately a fifth of the full dose for a 70-kg adult)
and this should reduce the risk of hypersensitivity reactions
while also minimising iron overload if repeated imaging is
needed.
Traditional contrast-enhanced MRA employs timed, first-
pass imaging of a GBCA bolus, focused on the arterial or
venous territory of interest. For the majority of GBCAs, the
volume of distribution is the extracellular fluid space which is
quickly accessed after a relatively short time within the blood
pool; hence, the time window for a vascular phase is very
short. Ferumoxytol has a prolonged intravascular half-life of
approximately 14.5 h [19] which allows for a longer time
window for data acquisition, higher spatial resolution during
the equilibrium phase and repeat imaging, if necessary, with
negligible loss of intravascular SI [20–22]. FeMRA has been
used for both arteriography [5, 7] and venography [8, 10] in
patients with CKD and has been shown to provide excellent
visualisation of both central and peripheral vessels without the
confounding effect of dense vascular calcification on luminal
assessment often seen at CT. On the downside, the agent can
be present in the blood pool for weeks following administra-
tion and months in the reticuloendothelial system, potentially
complicating the appearance of follow-up studies [23]. This
should be ameliorated with minimised dose.
Ferumoxytol has an iron oxide core encapsulated by a
semisynthetic carbohydrate that is substantially different from
prior dextran compounds, which diminishes immunogenicity,
Table 3 Predicted CNR in abdominal aorta and IVC following
ferumoxytol dose increments calculated by the regression equations
Ferumoxytol dose (mg/kg) Predicted peak CNR
in AA (%)
Predicted peak CNR
in IVC (%)
0 − 34 − 38
1 19 8
2 58 46
3 85 75
4 98 95
5 98 106
6 85 109
Table 4 Predicted SNR in abdominal aorta and IVC following
ferumoxytol dose increments calculated by the regression equations
Ferumoxytol dose
(mg/kg)
Predicted peak SNR in
AA (%)
Predicted peak SNR in
IVC (%)
0 31 27
1 83 73
2 121 109
3 145 135
4 155 152
5 151 159
6 133 157
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retards phagocytosis and slows the release of elemental iron
from the core. Ferumoxytol has an established safety profile
and has no known long-term toxicity [24]. Rates of adverse
events have been similar to those seen with iodine-based con-
trast [24] and the more commonly used intravenous iron for-
mulations [25]. The main concern has been reported cases of
anaphylactic-type reactions with rapid therapeutic bolus injec-
tions of undiluted compound leading to the recent recommen-
dations by the US FDA for controlled infusion of dilute
ferumoxytol [26]. In our study, no adverse events occurred
and there was no change in the recorded vital signs during
or after administration of ferumoxytol.
Fig. 4 Plane cross-sections of
aortic bifurcation before
ferumoxytol administration and
after serial dose increments. (a)
Pre-contrast, (b) 0.4 mg/kg, (c)
0.8 mg/kg, (d) 1.2 mg/kg, (e)
1.6 mg/kg, (f) 2 mg/kg, (g)
3 mg/kg and (h) 4 mg/kg
Fig. 3 Serial arterial phasemaximum intensity projection (MIP) coronal and axial images of abdominal and aortoiliac vasculature after each increment of
ferumoxytol. (a) Pre-contrast and after administration of (b) 1 mg/kg, (c) 2 mg/kg, (d) 3 mg/kg and (e) 4 mg/kg of ferumoxytol
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This study has notable strengths. We used a consistent pro-
tocol with standardised infusion rates and imaging parameters;
hence, differences in exposure to ferumoxytol were minimised.
Instead of allocating patients into fixed-dose groups, all patients
received multiple dose increments allowing for intra- and
interpatient dose comparisons. To balance between risk and
benefit, the optimal ferumoxytol dose was selected on the basis
of maximising signal while maintaining a low-risk threshold
rather on the basis of achieving the peak predicted signal.
Our study has several limitations. This is a single-centre study
with a relatively small number of patients. However, we used a
sequential design to eliminate variations in demographic and
Fig. 5 Plane cross-sections below
the level of the bifurcation of the
common iliac arteries before
ferumoxytol administration and
after serial dose increments. (a)
Pre-contrast, (b) 0.4 mg/kg, (c)
0.8 mg/kg, (d) 1.2 mg/kg, (e)
1.6 mg/kg, (f) 2 mg/kg, (g)
3 mg/kg and (h) 4 mg/kg
Fig. 6 Steady-state coronal thin
slab (6mm) maximum intensity
projection (MIP) images of the
left below knee vasculature at
level of tibial plateau and proxi-
mal fibula with ferumoxytol-
enhanced MRA. Magnified im-
ages showing details of distal
popliteal and proximal tibial ar-
tery branching
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clinical factors and detect changes in signal after studying a small
set of patients. Translation of the current protocol to 1.5 T needs to
be studied but this should be feasible with alterations to echo time
etc. to ensure reliable vascular enhancement. Lastly, we have
examined dose based upon body weight; however, theoretically,
the dose should be based upon the patient’s intravascular blood
volumewhich does not linearly increasewith bodyweight; hence,
a relatively lower dose may be appropriate for larger patients.
Using a consistent dosing regimen for contrast administra-
tion, we have shown that 3 mg/kg of ferumoxytol is effective
for MR angiography in CKD patients in whom there are con-
cerns in regard to standard contrast-based vascular imaging
methods. In the era of growing use of ferumoxytol for diag-
nostic MR applications, this study fills unmet clinical needs
by offering an effective dosing regimen.
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